At the EUHA congress, Sonova Holding presented two new products aimed at different parts of its hearing care business: Roger On Sphere, an AI-assisted remote microphone, and Integro CI, a cochlear implant sound processor family that has received TÜV approval and is beginning to launch in select European markets. The announcements matter less as standalone gadgets than as signals of where Sonova is trying to strengthen its product lineup.
What the new hardware actually does
Roger On Sphere is a remote microphone, a device hearing aid wearers use to pick up speech more clearly in noisy environments or at a distance, with added AI processing meant to improve how it isolates and transmits sound. Integro CI is a new processor for cochlear implants, the external component that converts sound into signals sent to the implanted electrode array. TÜV approval, a European testing and certification mark, indicates the device has met applicable safety and performance standards required for market entry in Europe, where initial availability is being rolled out first.
Why the implant segment is the real focus
Sonova's Cochlear Implants segment has faced revenue pressure in recent periods, and analysts already track profitability improvement there as a key variable in the company's outlook. A new processor family targets that specific weak spot, and it also tests whether Sonova can sell a more integrated two-ear hearing system that combines implants with its broader retail and audiological care network. Whether this translates into stronger results will depend on regulatory clearance in additional markets beyond the initial European launches and on how quickly clinics and patients adopt the new processor.
Risks that the product launch does not resolve
Sonova's broader business still depends on demand and pricing trends in Audiological Care and cochlear implants, particularly in Europe, and remains exposed to currency swings tied to a strong Swiss franc. The company is also midway through a CHF 90 million operational savings program. Roger On Sphere and Integro CI may support Sonova's competitive position, but they do not change underlying reimbursement policies, foreign-exchange exposure, or how effectively the company generates new patient leads.
What the numbers suggest
Current analyst projections point to Sonova reaching roughly CHF 4.4 billion in revenue and CHF 775.8 million in earnings by 2029, based on an assumed 6.8% annual revenue growth rate and an earnings increase of about CHF 238.7 million from today's CHF 537.1 million. More optimistic forecasts go further, estimating up to CHF 4.7 billion in revenue and CHF 902.2 million in earnings by the same year. These figures are projections, not guarantees, and the newly launched products' actual commercial performance will determine which estimates prove closer to reality.